Related Experiment Videos
Neoadjuvant chemotherapy in invasive bladder cancer
Aristotle Bamias1, Meletios A Dimopoulos
1Department of Clinical Therapeutics, Medical School, University of Athens, Haidari, 124 62 Athens, Greece. abamias@med.uoa.gr
Expert Review of Anticancer Therapy
|December 13, 2005
Summary
Neoadjuvant chemotherapy, particularly cisplatin-based regimens, significantly improves survival for muscle-invasive bladder cancer. Preoperative chemotherapy also aids in downstaging, a key factor for better patient prognosis.
Area of Science:
- Uro-oncology
- Medical oncology
- Clinical research
Background:
- Muscle-invasive bladder cancer (MIBC) treatment landscape.
- Evolving role of neoadjuvant chemotherapy (NAC).
Purpose of the Study:
- Clarify the role of NAC in MIBC.
- Evaluate NAC's impact on survival and downstaging.
- Discuss NAC within bladder preservation strategies.
Main Methods:
- Review of recent randomized studies and meta-analyses.
- Analysis of large Phase II and randomized clinical trials.
- Examination of bladder preservation approaches.
Main Results:
- Cisplatin-based combination chemotherapy provides a significant survival advantage in MIBC.
- Neoadjuvant chemotherapy leads to significant downstaging, correlating with favorable prognosis.
- Optimal sequencing of perioperative chemotherapy remains an open question.
Conclusions:
- Neoadjuvant chemotherapy is a vital component of MIBC treatment, enhancing survival.
- Downstaging achieved through NAC is a critical prognostic indicator.
- Further research is needed to optimize perioperative chemotherapy sequencing and improve therapeutic efficacy.